Drugs commonly associated with weight change: Umbrella systematic review and meta-analysis (Protocol)

Juan P. Domecq, Gabriela Prutsky, Zhen Wang, Tarig Elraiyah, Juan Brito Campana, Karen Mauck, Mohammed H. Lababidi, Aaron Leppin, Salman Fidahussein, Larry J. Prokop, Victor Manuel Montori, Mohammad H Murad

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions.Objective: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change.Methods/Design: Umbrella systematic review and meta-analysis of randomized controlled trials.We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts' panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m2). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will provided. We will use the I2 statistic and Cochran's Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence.Discussion: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies.

Original languageEnglish (US)
Article number44
JournalSystematic Reviews
Volume1
Issue number1
DOIs
StatePublished - Sep 29 2012

Fingerprint

Meta-Analysis
Weights and Measures
Pharmaceutical Preparations
Randomized Controlled Trials
Weight Gain
Weight Loss
Physicians
Publication Bias
Placebos
Guidelines
Confidence Intervals
Incidence
Health
Therapeutics

Keywords

  • Adults
  • Drug
  • Leptogenic
  • Obesogenic
  • Systematic review
  • Weight change
  • Weight gain
  • Weight loss

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Drugs commonly associated with weight change : Umbrella systematic review and meta-analysis (Protocol). / Domecq, Juan P.; Prutsky, Gabriela; Wang, Zhen; Elraiyah, Tarig; Brito Campana, Juan; Mauck, Karen; Lababidi, Mohammed H.; Leppin, Aaron; Fidahussein, Salman; Prokop, Larry J.; Montori, Victor Manuel; Murad, Mohammad H.

In: Systematic Reviews, Vol. 1, No. 1, 44, 29.09.2012.

Research output: Contribution to journalArticle

Domecq, Juan P. ; Prutsky, Gabriela ; Wang, Zhen ; Elraiyah, Tarig ; Brito Campana, Juan ; Mauck, Karen ; Lababidi, Mohammed H. ; Leppin, Aaron ; Fidahussein, Salman ; Prokop, Larry J. ; Montori, Victor Manuel ; Murad, Mohammad H. / Drugs commonly associated with weight change : Umbrella systematic review and meta-analysis (Protocol). In: Systematic Reviews. 2012 ; Vol. 1, No. 1.
@article{ea89ba62a2d347e69d8b764fb6d0d7b0,
title = "Drugs commonly associated with weight change: Umbrella systematic review and meta-analysis (Protocol)",
abstract = "Background: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions.Objective: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change.Methods/Design: Umbrella systematic review and meta-analysis of randomized controlled trials.We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts' panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m2). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95{\%} confidence interval will provided. We will use the I2 statistic and Cochran's Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence.Discussion: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies.",
keywords = "Adults, Drug, Leptogenic, Obesogenic, Systematic review, Weight change, Weight gain, Weight loss",
author = "Domecq, {Juan P.} and Gabriela Prutsky and Zhen Wang and Tarig Elraiyah and {Brito Campana}, Juan and Karen Mauck and Lababidi, {Mohammed H.} and Aaron Leppin and Salman Fidahussein and Prokop, {Larry J.} and Montori, {Victor Manuel} and Murad, {Mohammad H}",
year = "2012",
month = "9",
day = "29",
doi = "10.1186/2046-4053-1-44",
language = "English (US)",
volume = "1",
journal = "Systematic Reviews",
issn = "2046-4053",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Drugs commonly associated with weight change

T2 - Umbrella systematic review and meta-analysis (Protocol)

AU - Domecq, Juan P.

AU - Prutsky, Gabriela

AU - Wang, Zhen

AU - Elraiyah, Tarig

AU - Brito Campana, Juan

AU - Mauck, Karen

AU - Lababidi, Mohammed H.

AU - Leppin, Aaron

AU - Fidahussein, Salman

AU - Prokop, Larry J.

AU - Montori, Victor Manuel

AU - Murad, Mohammad H

PY - 2012/9/29

Y1 - 2012/9/29

N2 - Background: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions.Objective: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change.Methods/Design: Umbrella systematic review and meta-analysis of randomized controlled trials.We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts' panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m2). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will provided. We will use the I2 statistic and Cochran's Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence.Discussion: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies.

AB - Background: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions.Objective: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change.Methods/Design: Umbrella systematic review and meta-analysis of randomized controlled trials.We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts' panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m2). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will provided. We will use the I2 statistic and Cochran's Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence.Discussion: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies.

KW - Adults

KW - Drug

KW - Leptogenic

KW - Obesogenic

KW - Systematic review

KW - Weight change

KW - Weight gain

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=84876195864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876195864&partnerID=8YFLogxK

U2 - 10.1186/2046-4053-1-44

DO - 10.1186/2046-4053-1-44

M3 - Article

C2 - 23020969

AN - SCOPUS:84876195864

VL - 1

JO - Systematic Reviews

JF - Systematic Reviews

SN - 2046-4053

IS - 1

M1 - 44

ER -